Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7057-06: Once-weekly vs twice-weekly carfilzomib + dexamethasone in relapsed/refractory multiple myeloma
jRCT2080222914Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Ono Pharmaceutical. Started Jul 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222914.